Fairvalue-Calculator Fairvalue-Calculator

Medios AG (MEDOF) Fair Value & Analysis

Healthcare · US · Market cap $1.3B

Price$50.00
Fair Value$20.35
Upside-59.3%
Quality95/100
Evidence: High Range $12.98 – $27.71

Analysis

Medios AG (MEDOF) currently trades at $50.00, while our model-based Fair Value estimate is $20.35 — implying the stock looks roughly 59.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) -80% Cencora, Inc (C1CO34) -89% Cardinal Health, Inc (CAH) -36% Sigma Healthcare Limited (SIGGF) -67% Sitka Gold Corp (SIG) -88% Shanghai Pharmaceuticals Holding (601607) +255%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.